Does Prestroke Antiplatelet Therapy Increase the Risk of Symptomatic Intracranial Hemorrhage in Patients Receiving Tissue Plasminogen Activator for Acute Ischemic Stroke?

Ann Emerg Med. 2018 Mar;71(3):416-418. doi: 10.1016/j.annemergmed.2017.03.013. Epub 2017 Apr 29.

Authors

Clark G Owyang¹, Cappi Lay¹

Affiliation

¹ The Department of Emergency Medicine/Neurocritical Care, Mount Sinai School of Medicine, New York, NY.

PMID: 28460862
DOI: 10.1016/j.annemergmed.2017.03.013

No abstract available

Publication types

Editorial

MeSH terms

Brain Ischemia / drug therapy*
Drug Therapy, Combination
Global Health
Humans
Incidence
Intracranial Hemorrhages / epidemiology*
Platelet Aggregation Inhibitors / therapeutic use*
Risk Assessment*
Risk Factors
Tissue Plasminogen Activator / therapeutic use*

Substances

Platelet Aggregation Inhibitors
Tissue Plasminogen Activator